1. Home
  2. EOS vs RAPP Comparison

EOS vs RAPP Comparison

Compare EOS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Enhance Equity Income Fund II

EOS

Eaton Vance Enhance Equity Income Fund II

HOLD

Current Price

$22.47

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$26.58

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOS
RAPP
Founded
2005
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
EOS
RAPP
Price
$22.47
$26.58
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$47.80
AVG Volume (30 Days)
84.1K
368.4K
Earning Date
01-01-0001
03-10-2026
Dividend Yield
6.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$6.43
52 Week High
$20.63
$42.27

Technical Indicators

Market Signals
Indicator
EOS
RAPP
Relative Strength Index (RSI) 39.76 44.91
Support Level $22.19 $25.51
Resistance Level $22.77 $27.87
Average True Range (ATR) 0.29 1.47
MACD -0.04 -0.06
Stochastic Oscillator 22.19 35.05

Price Performance

Historical Comparison
EOS
RAPP

About EOS Eaton Vance Enhance Equity Income Fund II

Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: